Provincial government roles in Chinese tourism development: the case of Hunan.
In: Tourism and transition: governance, transformation and development, S. 169-183
14 Ergebnisse
Sortierung:
In: Tourism and transition: governance, transformation and development, S. 169-183
In: East Asia: an international quarterly, Band 16, Heft 1-2, S. 110-129
ISSN: 1096-6838
Cruising in the Global Economy: Profits, Pleasure and Work at Sea Author: Chin, C. B. N. Ashgate Publishing Company 2008, xii + 184 pp. ISBN 978-0-7546-7242-5 Contemporary Hospitality & Tourism: Management issues in China and India Authors: Ball, S., Horner, S. and Nield, K. Butterworth-Heinemann 2007, 195pp ISBN 978-0-7506-6856-9 The Literary Tourist Author: N. Watson Palgrave Macmillan, Basingstoke, 2008 pp 256 ISBN 13 9780 230 21092 9 (Pbk) Post-Conflict Heritage, Postcolonial Tourism – Culture, Politics and Development at Angkor. Author: Tim Winter Routledge. 2007 pp 200 ISBN978-0-415-43095-1 Tourism Management: Analysis, Behaviour and Strategy Editors: Woodside, A. and Martin, D. CAB International 2007 pp 592 ISBN: 9781845933234
BASE
In: The British journal of social work, Band 42, Heft 6, S. 1039-1059
ISSN: 1468-263X
In: Natural hazards and earth system sciences: NHESS, Band 11, Heft 4, S. 1153-1162
ISSN: 1684-9981
Abstract. During the 12 May 2008 Wenchuan earthquake, a large landslide of approximately 30 million m3 occurred at Donghekou with a particle run-out distance of over 2000 m. This paper presents fascinating particle flow and segregation characteristics in the landslide process found through field investigation of changes in the soil particle size, density, and fabric along the particle movement paths. The soil particles experienced projection, long-distance flying, sliding, and rolling. Trajectory segregation, inverse grading, and particle crushing were found in the landslide event, which contributed to the heterogeneity of the soil deposits. In the initial deposition area, particles with larger diameters appeared to have flown longer. Materials from different sources mixed, forming more uniform debris. In the run-out area, the particle flow tended to cause large particles to travel further. However, particle disintegration and crushing led to more small particles along the movement paths and the observed characteristic flow distances of very large particles did not increase with the particle diameter, which is different from observations of an idealized granular mass flow.
In: Natural hazards and earth system sciences: NHESS, Band 15, Heft 4, S. 885-893
ISSN: 1684-9981
Abstract. The determination of rockfall impact force is crucial in designing protection measures. In the present study, laboratory tests are carried out by testing the weight and shape of the falling rock fragments, drop height, incident angle, platform on the slideway, and cushion layer on the protection measures to investigate their influences on the impact force. The test results indicate that the impact force is positively exponential to the weight of rockfall and the instantaneous impact velocity of the rockfall approaching the protection measures. The impact velocity is found to be dominated not only by the drop height but also by the shape of rockfall and the length of the platform on the slideway. A great drop height and/or a short platform produces a fast impact velocity. Spherical rockfalls experience a greater impact velocity than cubes and elongated cuboids. A layer of cushion on the protection measures may reduce the impact force to a greater extent. The reduction effects are dominated by the cushion material and the thickness of the cushion layer. The thicker the cushion layer, the greater the reduction effect and the less the impact force. The stiffer the buffer material, the lower the buffering effect and the greater the impact force. The present study indicates that the current standard in China for designing protection measures may overestimate the impact force by not taking into consideration the rockfall shape, platform, and cushion layer.
Natural disasters cause considerable losses to people's lives and property. Satellite images can provide crucial information of the affected areas for the first time, conducive to relieving the people in disaster and reducing the economic loss. However, the traditional satellite image analysis method based on manual processing drains workforce and material resources, which slowed the government's response to the disaster. Aiming at the natural disasters like floods and earthquakes that often happen in the south of China, we propose a dual-stage damage assessment method based on LEDNet and ResNet. Our method detects the changes between the satellite images captured before and after a disaster of the same area, segments the buildings, and evaluates the damage level of affected buildings. In addition, we calculate influence maps based on the damage scale to the building and estimate the damage situation for electrical facilities. We used images related to earthquakes and floods in the xBD dataset to train the network model. Moreover, qualitative and quantitative evaluations demonstrated that our method has higher accuracy than the xBD baseline.
BASE
Background: DNA methylation at the GFI1-locus has been repeatedly associated with exposure to smoking from the foetal period onwards. We explored whether DNA methylation may be a mechanism that links exposure to maternal prenatal smoking with offspring's adult cardio-metabolic health.Methods: We meta-analysed the association between DNA methylation at GFI1-locus with maternal prenatal smoking, adult own smoking, and cardio-metabolic phenotypes in 22 population-based studies from Europe, Australia, and USA (n= 18,212). DNA methylation at the GFI1-locus was measured in whole-blood. Multivariable regression models were fitted to examine its association with exposure to prenatal and own adult smoking. DNA methylation levels were analysed in relation to body mass index (BMI), waist circumference (WC), fasting glucose (FG), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), diastolic, and systolic blood pressure (BP).Findings: Lower DNA methylation at three out of eight GFI1-CpGs was associated with exposure to maternal prenatal smoking, whereas, all eight CpGs were associated with adult own smoking. Lower DNA methylation at cg14179389, the strongest maternal prenatal smoking locus, was associated with increased WC and BP when adjusted for sex, age, and adult smoking with Bonferroni-corrected P < 0.012. In contrast, lower DNA methylation at cg09935388, the strongest adult own smoking locus, was associated with decreased BMI, WC, and BP (adjusted 1 x 10(-7) < P < 0.01). Similarly, lower DNA methylation at cg12876356, cg18316974, cg09662411, and cg18146737 was associated with decreased BMI and WC (5 x 10(-8) < P < 0.001). Lower DNA methylation at all the CpGs was consistently associated with higher TG levels.Interpretation: Epigenetic changes at the GFI1 were linked to smoking exposure in-utero/in-adulthood and robustly associated with cardio-metabolic risk factors. Fund: European Union's Horizon 2020 research and innovation programme under grant agreement no. 633595 DynaHEALTH. (c) 2018 The Authors. Published by Elsevier B.V.
BASE
In: Parmar , P , Lowry , E , Cugliari , G , Suderman , M , Wilson , R , Karhunen , V , Andrew , T , Wiklund , P , Wielscher , M , Guarrera , S , Teumer , A , Lehne , B , Milani , L , de Klein , N , Mishra , P , Melton , P , Mandaviya , P , Kasela , S , Nano , J , Zhang , W , Zhang , Y , Uitterlinden , A , Peters , A , Schottker , B , Gieger , C , Anderson , D , Boomsma , D , Grabe , H , Panico , S , Veldink , J , van Meurs , J , van den Berg , L , Beilin , L , Franke , L , Loh , M , van Greevenbroek , M , Nauck , M , Kahonen , M , Hurme , M , Raitakari , O , Franco , O , Slagboom , P , van der Harst , P , Kunze , S , Felix , S , Zhang , T , Chen , W , Mori , T , Bonnefond , A , Heijmans , B , Muka , T , Kooner , J , Fischer , K , Waldenberger , M , Froguel , P , Huang , R , Lehtimaki , T , Rathman , W , Relton , C , Matullo , G , Brenner , H , Verweij , N , Li , S , Chambers , J , Jarvelin , M-R & Sebert , S 2018 , ' Association of maternal prenatal smoking GFI1-locus and cardio-metabolic phenotypes in 18,212 adults ' , EBioMedicine , vol. 38 , pp. 206-216 . https://doi.org/10.1016/j.ebiom.2018.10.066
Background:DNA methylation at theGFI1-locus has been repeatedly associated with exposure to smoking fromthe foetal period onwards. We explored whether DNA methylation may be a mechanism that links exposure tomaternal prenatal smoking with offspring's adult cardio-metabolic health.Methods:We meta-analysed the association between DNA methylation atGFI1-locus with maternal prenatalsmoking, adult own smoking, and cardio-metabolic phenotypes in 22 population-based studies from Europe,Australia, and USA (n= 18,212). DNA methylation at theGFI1-locus was measured in whole-blood. Multivari-able regression models werefitted to examine its association with exposure to prenatal and own adult smoking.DNA methylation levels were analysed in relation to body mass index (BMI), waist circumference (WC), fastingglucose (FG), high-density lipoprotein cholesterol (HDL—C), triglycerides (TG), diastolic, and systolic blood pres-sure (BP).Findings:Lower DNA methylation at three out of eightGFI1-CpGs was associated with exposure to maternal pre-natal smoking, whereas, all eight CpGs were associated with adult own smoking. Lower DNA methylation atcg14179389, the strongest maternal prenatal smoking locus, was associated with increased WC and BP when ad-justed for sex, age, and adult smoking with Bonferroni-correctedPb0·012. In contrast, lower DNA methylationatcg09935388,thestrongest adultownsmokinglocus, wasassociated with decreasedBMI, WC,and BP (adjusted1×10−7bPb0.01). Similarly, lower DNA methylation at cg12876356, cg18316974, cg09662411, andcg18146737 was associated with decreased BMI and WC (5 × 10−8bPb0.001). Lower DNA methylation at allthe CpGs was consistently associated with higher TG levels.Interpretation:Epigenetic changes at theGFI1were linked to smoking exposurein-utero/in-adulthood and ro-bustly associated with cardio-metabolic risk factors.Fund:European Union's Horizon 2020 research and innovation programme under grant agreement no. 633595DynaHEALTH.
BASE
Background: DNA methylation at the GFI1-locus has been repeatedly associated with exposure to smoking from the foetal period onwards. We explored whether DNA methylation may be a mechanism that links exposure to maternal prenatal smoking with offspring's adult cardio-metabolic health. Methods: We meta-analysed the association between DNA methylation at GFI1-locus with maternal prenatal smoking, adult own smoking, and cardio-metabolic phenotypes in 22 population-based studies from Europe, Australia, and USA (n = 18,212). DNA methylation at the GFI1-locus was measured in whole-blood. Multivariable regression models were fitted to examine its association with exposure to prenatal and own adult smoking. DNA methylation levels were analysed in relation to body mass index (BMI), waist circumference (WC), fasting glucose (FG), high-density lipoprotein cholesterol (HDL—C), triglycerides (TG), diastolic, and systolic blood pressure (BP). Findings: Lower DNA methylation at three out of eight GFI1-CpGs was associated with exposure to maternal prenatal smoking, whereas, all eight CpGs were associated with adult own smoking. Lower DNA methylation at cg14179389, the strongest maternal prenatal smoking locus, was associated with increased WC and BP when adjusted for sex, age, and adult smoking with Bonferroni-corrected P < 0·012. In contrast, lower DNA methylation at cg09935388, the strongest adult own smoking locus, was associated with decreased BMI, WC, and BP (adjusted 1 × 10−7 < P < 0.01). Similarly, lower DNA methylation at cg12876356, cg18316974, cg09662411, and cg18146737 was associated with decreased BMI and WC (5 × 10−8 < P < 0.001). Lower DNA methylation at all the CpGs was consistently associated with higher TG levels. Interpretation: Epigenetic changes at the GFI1 were linked to smoking exposure in-utero/in-adulthood and robustly associated with cardio-metabolic risk factors. Fund: European Union's Horizon 2020 research and innovation programme under grant agreement no. 633595 DynaHEALTH.
BASE
Abstract Background: DNA methylation at the GFI1-locus has been repeatedly associated with exposure to smoking from the foetal period onwards. We explored whether DNA methylation may be a mechanism that links exposure to maternal prenatal smoking with offspring's adult cardio-metabolic health. Methods: We meta-analysed the association between DNA methylation at GFI1-locus with maternal prenatal smoking, adult own smoking, and cardio-metabolic phenotypes in 22 population-based studies from Europe, Australia, and USA (n = 18,212). DNA methylation at the GFI1-locus was measured in whole-blood. Multivariable regression models were fitted to examine its association with exposure to prenatal and own adult smoking. DNA methylation levels were analysed in relation to body mass index (BMI), waist circumference (WC), fasting glucose (FG), high-density lipoprotein cholesterol (HDL—C), triglycerides (TG), diastolic, and systolic blood pressure (BP). Findings: Lower DNA methylation at three out of eight GFI1-CpGs was associated with exposure to maternal prenatal smoking, whereas, all eight CpGs were associated with adult own smoking. Lower DNA methylation at cg14179389, the strongest maternal prenatal smoking locus, was associated with increased WC and BP when adjusted for sex, age, and adult smoking with Bonferroni-corrected P < 0·012. In contrast, lower DNA methylation at cg09935388, the strongest adult own smoking locus, was associated with decreased BMI, WC, and BP (adjusted 1 × 10⁻⁷ < P < 0.01). Similarly, lower DNA methylation at cg12876356, cg18316974, cg09662411, and cg18146737 was associated with decreased BMI and WC (5 × 10⁻⁸ < P < 0.001). Lower DNA methylation at all the CpGs was consistently associated with higher TG levels. Interpretation: Epigenetic changes at the GFI1 were linked to smoking exposure in-utero/in-adulthood and robustly associated with cardio-metabolic risk factors. Fund: European Union's Horizon 2020 research and innovation programme under grant agreement no. 633595 DynaHEALTH.
BASE
WOS: 000471758500010 ; PubMed ID: 31209238 ; The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells. ; AstraZenecaAstraZeneca; European Union Horizon 2020 research [668858 PrECISE]; Joint Research Center for Computational Biomedicine (Bayer AG); National Institute for Health Research (NIHR) Sheffield Biomedical Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences; Wellcome TrustWellcome Trust [102696, 206194] ; We thank the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the Wellcome Trust Sanger Institute for help with the preparation of the molecular data, Denes Turei for help with Omnipath, and Katjusa Koler for help with matching drug names across combination screens. We thank AstraZeneca for funding and provision of data to the DREAM Consortium to run the challenge, and funding from the European Union Horizon 2020 research (under grant agreement No 668858 PrECISE to J.S.R.), the Joint Research Center for Computational Biomedicine (which is partially funded by Bayer AG) to J.S.R., National Institute for Health Research (NIHR) Sheffield Biomedical Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences. M.G lab is supported by Wellcome Trust (102696 and 206194).
BASE
The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells. ; AstraZeneca ; European Union Horizon 2020 research [668858 PrECISE] ; Joint Research Center for Computational Biomedicine (Bayer AG) ; National Institute for Health Research (NIHR) Sheffield Biomedical Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences ; Wellcome Trust [102696, 206194] ; We thank the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the Wellcome Trust Sanger Institute for help with the preparation of the molecular data, Denes Turei for help with Omnipath, and Katjusa Koler for help with matching drug names across combination screens. We thank AstraZeneca for funding and provision of data to the DREAM Consortium to run the challenge, and funding from the European Union Horizon 2020 research (under grant agreement No 668858 PrECISE to J.S.R.), the Joint Research Center for Computational Biomedicine (which is partially funded by Bayer AG) to J.S.R., National Institute for Health Research (NIHR) Sheffield Biomedical Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences. M.G lab is supported by Wellcome Trust (102696 and 206194).
BASE
The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells. ; We thank the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the Wellcome Trust Sanger Institute for help with the preparation of the molecular data, Denes Turei for help with Omnipath, and Katjusa Koler for help with matching drug names across combination screens. We thank AstraZeneca for funding and provision of data to the DREAM Consortium to run the challenge, and funding from the European Union Horizon 2020 research (under grant agreement No 668858 PrECISE to J.S.R.), the Joint Research Center for Computational Biomedicine (which is partially funded by Bayer AG) to J.S.R., National Institute for Health Research (NIHR) Sheffield Biomedical Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy of Sciences. M.G lab is supported by Wellcome Trust (102696 and 206194).
BASE